2022 World Conference on Lung Cancer (ePosters)-EP02.01-004. Application of a Genomic Assay for Risk Stratification of Resected NSCLC in a Community Cancer Center Setting, a Pilot Study

EP02.01-004. Application of a Genomic Assay for Risk Stratification of Resected NSCLC in a Community Cancer Center Setting, a Pilot Study

Back to course

Pdf Summary

A pilot study was conducted to evaluate the use of a genomic assay called DetermaRx in the management of early-stage, non-squamous non-small cell lung cancer (NSCLC) after surgical resection in a community cancer center setting. The assay is designed to identify patients who may benefit from adjuvant chemotherapy based on their risk of recurrence.<br /><br />The study included 28 patients with resected stage I-IIA non-squamous NSCLC. A 14-gene molecular stratification test was performed on each surgical specimen using the DetermaRx assay, and the results were compared to the risk stratification based on the National Comprehensive Cancer Network (NCCN) criteria.<br /><br />The findings showed that a higher number of stage IA patients were identified as high-risk for recurrence by the molecular assay compared to the NCCN criteria. Specifically, 36.4% of stage IA2 patients and 71.4% of stage IA3 patients were classified as high-risk by the molecular assay, while only 27.3% and 28.6% of them, respectively, had NCCN high-risk features.<br /><br />For stage IB and IIA patients, the molecular assay and NCCN criteria had comparable risk stratification profiles. In both groups, around 75-83% of patients were classified as high-risk by both methods.<br /><br />The study suggests that the use of the genomic assay can help identify more stage IA patients at high-risk for recurrence compared to traditional criteria. Although adjuvant chemotherapy is not currently recommended for stage IA patients, utilizing molecular risk profiling may help accurately identify those who could benefit from this treatment.<br /><br />This pilot study demonstrates the potential applicability of the DetermaRx genomic assay in a community cancer center setting for risk stratification of resected NSCLC patients. Further research is needed to validate these findings and determine the impact of molecular risk profiling on treatment decisions in early-stage NSCLC.

Asset Subtitle

Hiroshi Yamagata

Meta Tag

Speaker Hiroshi Yamagata

Topic Early Stage Non-small Cell Lung Cancer - Biomarkers

Keywords

pilot study

genomic assay

DetermaRx

early-stage

NSCLC

surgical resection

adjuvant chemotherapy

risk of recurrence

molecular risk profiling

treatment decisions